The Role of Host-microbiota Interplay in Hidradenitis Suppurativa Pathogenesis

Inclusion Criteria: * Subject able to read, understand and give documented informed consent * Subject willing and able to comply with the protocol requirements for the duration of the study * Subject with health insurance coverage according to local regulations * For woman with childbearing potential, negative pregnancy test at the inclusion visit Specific criteria for HS patients * Subject diagnosed with HS for at least 6 months * Subject diagnosed with moderate-to-severe HS defined by HS PGA≥3 * Subject presenting an HS with inflammatory phenotype defined by the presence of folliculitis, nodules and/or abcesses * Subject suffering from at least 4 flares/year and presenting 5 active inflammatory lesions (nodules and/or abcesses) Exclusion Criteria: * Pregnancy or breast-feeding women * Subject treated by allergen immunotherapy within 4 weeks before inclusion * Subject treated by Non-Steroidal Anti-Inflammatory Drugs (NSAID), antibiotics or proton-pump inhibitors within 4 weeks before inclusion * Subject treated by live (attenuated) vaccine within 4 weeks before inclusion * Subject treated by anti-viral treatment within 4 weeks before inclusion * Subject treated by anti-diarrhea treatment including, but not limited to Loperamide * Subject treated by immunosuppressive/immunomodulatory substances including oral corticosteroid or biological agents within 4 weeks before inclusion * Subject presenting spondylo-arthritis or Inflammatory Bowel Disease (IBD) * Subject with a Body Mass Index (BMI)\<18.5 or BMI\>35 * Subject consuming probiotics or using a specific diet (e.g. gluten free, vegetarian, vegan, intermittent fasting) * Subject with any additional condition that, in the opinion of the investigator, may interfere with the assessment or put the subject at risk * Linguistic or mentally incapacity to sign the consent form * Subject protect by the law (adult under guardianship, or hospitalized in a public or private institution for a reason other than study, or incarcerated) * Subject in an exclusion period from a previous study or who is participating in another clinical trial using a drug Specific criteria for HS patients * Subject currently experiencing or having a history of other concomitant skin conditions that would interfere with evaluation of HS * History of allergic reaction to local anesthetic product * History of wound healing disorders (e.g. hypertrophic scars, keloids) * History of extensive armpit surgery * Subject with known active infection to Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) * Subject treated for their HS by systemic therapy, investigational or commercial, approved or off label) * Subject treated for their HS by immunosuppressants or intralesional corticosteroids within 4 weeks before the inclusion * Subject treated for their HS by topical antibiotics within 4 weeks before the inclusion * Subject previously treated with monoclonal antibodies